Skip to main content
Clinical Trials/KCT0005710
KCT0005710
Not yet recruiting
未知

A multicenter randomized exploratory clinical trial to evaluate the effect of bone metabolism and the efficacy of evogliptin and dapagliflozin for blood sugar in the menopause female patients with osteopenia and type 2 diabetes.

Kyung Hee University Hospital at Gangdong0 sites120 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Kyung Hee University Hospital at Gangdong
Enrollment
120
Status
Not yet recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional Study
Sex
Female

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\) Postmenopausal women between 40 and 70 years of age with type 2 diabetes patients who are not taking diabetes drugs or who are not controlled by blood sugar at 7\.0%\= HbA1c \< 9\.0% while taking metformin
  • ? Menopause corresponds when one or more of the following three conditions are satisfied.
  • ? 12 months of amenorrhea
  • ? In the case of FSH\=40 mIU/mL in women over 50 years who have undergone hysterectomy or 6 months of amenorrhea
  • ? Patients 6 weeks after ovariectomy
  • 2\) Lumbar, neck of femur and total femur bone density measurements were \-2\.4\=T\-score\<\-1\.0
  • 3\) Obtained written informed consent from a patient
  • 4\) Patients who can participate during clinical trials and perform all planned trial procedures and visits.

Exclusion Criteria

  • 1\) A person who has taken a diabetes medications other than metformin within 12 weeks, or who is hypersensitivity to DPP4 inhibitors or SGLT2 inhibitors.
  • 2\) AST or ALT exceeds 2 times the upper limit of the normal range in laboratory tests
  • 3\) Patients with moderate or severe renal impairment, end\-stage renal disease (ESRD) or dialysis
  • 4\) Patients whose eGFR (using MDRD formula) calculated using serum creatinine results within 4 weeks before screening or at screening is less than 60 mL/minute/1\.73 m2
  • 5\) In case of osteoporosis medication dosage as follows:
  • \- Patients who have ever used bisphosphonate formulations
  • \- Patients who have used female hormones, SERM, denosumab, and parathyroid hormone preparations within 12 months
  • 6\) Have bone or mineral metabolic diseases or have received treatment that affects them
  • \- Oral steroid 2\.5mg or more has been continuously taken for more than 3 months from the date of consent
  • \- Continuous use of systemic or inhaled steroids for more than 3 months from the date of consent

Outcomes

Primary Outcomes

Not specified

Similar Trials